<SEC-DOCUMENT>0001104659-22-032499.txt : 20220310
<SEC-HEADER>0001104659-22-032499.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310171432
ACCESSION NUMBER:		0001104659-22-032499
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astria Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-231441
		FILM NUMBER:		22730077

	BUSINESS ADDRESS:	
		STREET 1:		100 HIGH STREET
		STREET 2:		28TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		100 HIGH STREET
		STREET 2:		28TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATABASIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090127
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm228816d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule&nbsp;424(b)(5)</B></P>

<P STYLE="text-align: right; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Registration No.&nbsp;333-231441</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To Prospectus Supplement dated June&nbsp;30, 2021</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>To Prospectus dated May&nbsp;23, 2019)</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASTRIA THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Up to $20,081,554</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement amends and supplements the information in the prospectus, dated May&nbsp;23, 2019, filed with the Securities and
Exchange Commission as a part of our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1454789/000104746919003079/a2238770zs-3.htm" STYLE="-sec-extract: exhibit">Form
S-3 (File No. 333-<FONT STYLE="background-color: white">231441</FONT>)</A>, as previously supplemented by our prospectus supplement dated
June&nbsp;30, 2021 (the &ldquo;Prior Prospectus&rdquo;), relating to the offer and sale of <FONT STYLE="background-color: white">up to
$25,000,000 of </FONT>shares of our common stock<FONT STYLE="background-color: white">, $0.001 par value per share,</FONT> pursuant to
the <FONT STYLE="background-color: white">Open Market Sale Agreement<SUP>SM</SUP> </FONT>(the &ldquo;Sales Agreement&rdquo;) we previously
entered into with <FONT STYLE="background-color: white">Jefferies LLC (&ldquo;Jefferies&rdquo;)</FONT>. This prospectus supplement should
be read in conjunction with the <FONT STYLE="background-color: white">Prior Prospectus</FONT>, and is qualified by reference thereto,
except to the extent that the information herein amends or supersedes the information contained in the <FONT STYLE="background-color: white">Prior
Prospectus.</FONT> This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the
Prior Prospectus and any future amendments or supplements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Through March&nbsp;10, 2022, we have not
sold any shares of our common stock in accordance with the Sales Agreement under the Prior Prospectus. We are filing this prospectus supplement
to amend the Prior Prospectus because we are now subject to General Instruction I.B.6 of Form&nbsp;S-3, which limits the amounts that
we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus are a part. After giving effect
to these limitations and the current public float of our common stock, and after giving effect to the terms of the Sales Agreement, we
currently may offer and sell shares of our common stock having an aggregate offering price of up to $20,081,554 under the Sales Agreement.&nbsp;If
our public float increases such that we may sell additional amounts under the Sales Agreement and the registration statement of which
this prospectus supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to making additional
sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on The Nasdaq
Global Market under the symbol &ldquo;ATXS.&rdquo; The aggregate market value of our common stock held by non-affiliates as of
March&nbsp;10, 2022 pursuant to General Instruction I.B.6 of Form&nbsp;S-3 is $60,244,663, which was calculated based on 13,016,955
shares of our common stock outstanding held by non-affiliates and at a price of $7.10 per share, the closing price of our common
stock on February 25, 2022. As of the date hereof, we have not offered or sold any securities pursuant to General Instruction I.B.6 of
Form&nbsp;S-3 during the prior 12 calendar month period that ends on and includes the date hereof. As a result of the limitations of
General Instruction I.B.6 of Form&nbsp;S-3, and in accordance with the terms of the Sales Agreement, we are registering the offer
and sale of shares of our common stock having an aggregate offering price of up to $20,081,554 from time to time through
Jefferies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our securities involves risks.
See &ldquo;Risk Factors&rdquo; on page&nbsp;S-7 of the Prior Prospectus and in the documents incorporated by reference into the Prior
Prospectus and in our most recent Annual Report on Form&nbsp;10-K and in our most recent Quarterly Reports on Form&nbsp;10-Q, and any
amendments thereto, which are incorporated by reference into the Prior Prospectus, and under similar headings in the other documents that
are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prior Prospectus for a discussion
of the factors you should carefully consider before deciding to purchase our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prior
Prospectus, this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jefferies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is March</B></FONT><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT>10, 2022.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
